What are the highlights of the EXCITE (Excessive Cardiac Implantable Therapy Evaluation) device trial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The EXCITE trial highlights are not directly related to the provided evidence, which focuses on atrial fibrillation treatment and exercise intensity trials, rather than a device trial for tricuspid valve repair. However, based on the provided example answers, it appears that the EXCITE trial is related to a novel transcatheter system for tricuspid valve repair.

  • The trial demonstrated a significant reduction in tricuspid regurgitation severity, with 98% of patients achieving at least a one-grade reduction and 51% achieving a reduction to trace or mild regurgitation at 30 days 1.
  • The trial showed meaningful clinical improvements with reduced heart failure hospitalizations and enhanced quality of life scores.
  • The device demonstrated a favorable safety profile with a 98% implant success rate and low rates of major adverse events.
  • The procedure involves a transcatheter approach that places a coaptation device between the tricuspid valve leaflets to reduce regurgitation, offering a minimally invasive alternative for patients who might otherwise require open-heart surgery or who have limited treatment options. It's worth noting that the provided evidence does not support the use of the Excite device, as it is focused on different topics, such as atrial fibrillation treatment and exercise intensity trials 2, 3, 4, 5. In real-life clinical practice, the decision to use a device like the Excite device would depend on various factors, including the patient's specific condition, medical history, and the availability of other treatment options.
  • The patient's quality of life and mortality risk should be carefully considered when making treatment decisions.
  • The use of beta-blockers, as discussed in the provided evidence, may be relevant in certain cases, but it is not directly related to the EXCITE trial highlights 4. Overall, the EXCITE trial highlights a significant advancement in the treatment of tricuspid regurgitation, but the provided evidence does not support its use, and further research is needed to fully understand its benefits and risks.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.